Triplebar
Enabler → Predictive Cellular Optimisation; Series A2
Los Angeles, California
Evolutionary intelligence.
Triplebar’s hyper-throughput platform shrinks the bioreactor down to the size of a nanodroplet. At this scale, they accurately screen hundreds of millions of cells in as little as a day to identify the best performing lines. It’s evolution as nature intended, only faster.
"Triplebar fast-tracks nature’s own wonderful process of discovery, unlocking breakthroughs in a fraction of the time."
Jeremy Agresti
CTO and Co-Founder of TriplebarThe Science
How does it work?
The Future
What does success look like?
Synthesis Collaboration
Synthesis has worked closely with Triplebar since their Series A round in 2023.
Why we backed them:
We’re excited about the potential for Triplebar’s AI-driven cell line platform to deliver a much-needed step-change in commercial outcomes for biomanufacturing businesses. From feeding the world with sustainable proteins to healing it with new cancer therapies, Triplebar fast-tracks nature’s own process of discovery, unlocking breakthroughs in a fraction of the time.
How Synthesis engaged:
Since leading Triplebar’s Series A round in 2023, we’ve worked closely with the team, helping guide the company’s strategic direction. Our support helped Triplebar advance the commercialisation of their proprietary technology platform, and to build key industry partnerships across biopharma and food as the company scales.
